AR055959A1 - Derivados espiro para la modulacion de actividad de crth2 - Google Patents

Derivados espiro para la modulacion de actividad de crth2

Info

Publication number
AR055959A1
AR055959A1 ARP060102148A ARP060102148A AR055959A1 AR 055959 A1 AR055959 A1 AR 055959A1 AR P060102148 A ARP060102148 A AR P060102148A AR P060102148 A ARP060102148 A AR P060102148A AR 055959 A1 AR055959 A1 AR 055959A1
Authority
AR
Argentina
Prior art keywords
alkyl
substituted
unsubstituted
heteroaryl
group
Prior art date
Application number
ARP060102148A
Other languages
English (en)
Original Assignee
Applied Research Systems
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Applied Research Systems filed Critical Applied Research Systems
Publication of AR055959A1 publication Critical patent/AR055959A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/10—Spiro-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/04—Antipruritics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/14—Decongestants or antiallergics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Abstract

Uso de derivados espiro de la formula (i) para el tratamiento y/o prevencion de enfermedades alérgicas, dermatosis inflamatorias, y otras enfermedades con un componente inflamatorio. Reivindicacion 1: A compuesto de acuerdo con la formula (I') donde R1 es seleccionado entre el grupo formado por hidrogeno, alquilo-C1-C6, alcoxi C1-C6, halo alquilo-C1-C6, halo-alcoxi-C1-C6, halogeno, arilo y heteroarilo; m es un entero seleccionado entre 0, 1, 2, 3 o 4; R2 es alquilo-C3-C6- o A; donde A es seleccionado entre el grupo formado por A1, A2, A3, A4, S5 y A6: -(CH2)n-R4 -(CH)n R7-R4 -(CH2)n-O-R4 -[ ]n-o-[ ]nR4 -[ ]n-o-[ ]n-o-R4 -(CH2)n-C(:o)-R4, en donde cada n es un entero independientemente seleccionado entre 1, 2, 3 o 4; donde R4 e3s seleccionado entre el grupo formado por alquilo-C2-C6, alquenilo-C2-C6, C3-C8-cicloalquilo, heterocicloalquilo- C3-C8, arilo y heteroarilo; cada R4 puede opcionalmente ser sustituido con uno o más grupos R6; cada R6 es independientemente seleccionado entre el grupo formado por alquilo-C1-C6, alcoxi, alcoxicarbonilo, arilo sustituido o no sustituido, aril alquilo-C1-C6 sustituido o no sustituido, heteroarilo sustituido o no sustituido, heteroaril alquilo-C1-C6 sustituido o no sustituido, C3-C8-cicloalquilo sustituido o no sustituido, C3-C8-heterocicloalquilo sustituido o no sustituido, carboxilo, ciano, halogeno, hidroxi, amino, aminocarbonilo, acilamino, nitro, sulfoxi, sulfonilo, sulfonilamina, aminosulfonilo y trihalo- alquilo-C1-C6, R7 es hidrogeno o alquilo-C1-C6; R3 es B, donde B es: -(CH2)n-R5donde n es un entero independientemente seleccionado entre 1, 2, 3 o 4; donde R5 es carboxi; X es CH2 o NH; cada Y es independientemente C(O) o CH2; y Z es C(O) o CHR7; As{i como sus isomeros geométricos, formas opticamente activas como enantiomeros, diastereomeros, sus formas racemato o sales farmacéuticamente aceptables de los mismos.
ARP060102148A 2005-05-24 2006-05-24 Derivados espiro para la modulacion de actividad de crth2 AR055959A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP05104428 2005-05-24
US68863105P 2005-06-08 2005-06-08

Publications (1)

Publication Number Publication Date
AR055959A1 true AR055959A1 (es) 2007-09-12

Family

ID=35478408

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP060102148A AR055959A1 (es) 2005-05-24 2006-05-24 Derivados espiro para la modulacion de actividad de crth2

Country Status (20)

Country Link
US (1) US8236963B2 (es)
EP (1) EP1891075B1 (es)
JP (1) JP5567268B2 (es)
KR (1) KR101333861B1 (es)
CN (1) CN101300259B (es)
AR (1) AR055959A1 (es)
AT (1) ATE529429T1 (es)
AU (1) AU2006251138C1 (es)
BR (1) BRPI0610209A2 (es)
CA (1) CA2602965C (es)
DK (1) DK1891075T3 (es)
ES (1) ES2375614T3 (es)
MX (1) MX2007014256A (es)
NZ (1) NZ562772A (es)
PL (1) PL1891075T3 (es)
PT (1) PT1891075E (es)
RU (1) RU2478639C2 (es)
UA (1) UA90145C2 (es)
WO (1) WO2006125784A1 (es)
ZA (1) ZA200709819B (es)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SI2051962T1 (sl) 2006-08-07 2012-02-29 Actelion Pharmaceuticals Ltd Derivati (3-amino-1,2,3,4-tetrahidro-9h-karbazol-9-il)-ocetne kisline
US20120115895A1 (en) 2009-07-15 2012-05-10 Merck Serono S.A. Tricyclic indole-derived spiro derivatives as crth2 modulators
NZ600430A (en) 2009-11-12 2014-06-27 Univ Michigan Spiro-oxindole mdm2 antagonists
KR101444572B1 (ko) 2010-03-22 2014-09-24 액테리온 파마슈티칼 리미티드 3-(헤테로아릴-아미노)-1,2,3,4-테트라히드로-9ｈ-카르바졸 유도체 및 이의 프로스타글란딘 ｄ2 수용체 조절제로서의 용도
EA201390682A1 (ru) 2010-11-12 2014-01-30 Дзе Риджентс Оф Дзе Юниверсити Оф Мичиган Спирооксиндольные антагонисты mdm2
EP2457900A1 (en) 2010-11-25 2012-05-30 Almirall, S.A. New pyrazole derivatives having CRTh2 antagonistic behaviour
ES2596581T3 (es) 2011-04-14 2017-01-10 Actelion Pharmaceuticals Ltd. Derivados de ácido 7-(heteroaril-amino)-6,7,8,9-tetrahidropirido[1,2-a]indol acético y su uso como moduladores del receptor de prostaglandina D2
JP2014513699A (ja) 2011-05-11 2014-06-05 ザ リージェンツ オブ ザ ユニバーシティ オブ ミシガン スピロ−オキシインドールｍｄｍ２アンタゴニスト
US20140328861A1 (en) 2011-12-16 2014-11-06 Atopix Therapeutics Limited Combination of CRTH2 Antagonist and a Proton Pump Inhibitor for the Treatment of Eosinophilic Esophagitis
CN103554118B (zh) * 2013-10-15 2015-08-19 华东师范大学 四氢呋喃并苯并二氢吡喃多环化合物及其应用
CN103554119B (zh) * 2013-10-15 2015-09-16 华东师范大学 四氢呋喃并苯并二氢吡喃多环化合物的制备方法
CN103554120B (zh) * 2013-10-16 2015-06-24 华东师范大学 3,3-螺(2-四氢呋喃)氧化吲哚多环状化合物的制备方法
CN103554121B (zh) * 2013-10-16 2015-06-24 华东师范大学 3,3-螺(2-四氢呋喃)氧化吲哚多环状化合物及其应用
MY179356A (en) 2014-03-17 2020-11-05 Idorsia Pharmaceuticals Ltd Azaindole acetic acid derivatives and their use as prostaglandin d2 receptor modulators
CA2938107A1 (en) 2014-03-18 2015-09-24 Actelion Pharmaceuticals Ltd Azaindole acetic acid derivatives and their use as prostaglandin d2 receptor modulators
WO2016149099A1 (en) 2015-03-13 2016-09-22 Forma Therapeutics, Inc. Alpha-cinnamide compounds and compositions as hdac8 inhibitors
CN107580598B (zh) * 2015-07-15 2020-11-13 豪夫迈·罗氏有限公司 作为代谢型谷氨酸受体调节剂的乙炔基衍生物
TWI711616B (zh) 2015-09-15 2020-12-01 瑞士商愛杜西亞製藥有限公司 結晶型式
RU2631856C1 (ru) * 2016-05-04 2017-09-27 Федеральное государственное бюджетное образовательное учреждение высшего образования "Чувашский государственный университет имени И.Н. Ульянова" Способ получения аммонийных солей 3-амино-8-гидрокси-1,6-диоксо-4-циано-2,7-диазаспиро[4.4]нон-3-ен-2-идов
PE20190382A1 (es) 2016-07-18 2019-03-08 Hoffmann La Roche Derivados etinilo
CN109384794B (zh) * 2017-08-08 2020-06-19 沈阳药科大学 质子酸催化的一类四环吲哚骨架的合成方法
CN109384787B (zh) * 2017-08-08 2021-04-16 沈阳药科大学 一种一价银催化的氢化吡啶螺二氢吲哚环的合成方法
CN109369658B (zh) * 2017-08-08 2020-01-31 沈阳药科大学 一种螺[吡咯烷-3,3`-氧化吲哚]环系的合成方法
KR101857408B1 (ko) * 2018-02-28 2018-05-14 경북대학교 산학협력단 탈모 예방 또는 치료용 조성물
CN112876488B (zh) * 2021-02-18 2021-12-21 苏州大学 螺环吲哚啉衍生物及其制备方法和应用

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IE52879B1 (en) 1981-05-12 1988-03-30 Ici Plc Pharmaceutical spiro-hydantoin derivatives
IE53102B1 (en) * 1981-05-12 1988-06-22 Ici Plc Pharmaceutical spiro-succinimide derivatives
US5948807A (en) * 1997-09-03 1999-09-07 Regents Of The University Of Minnesota Spiroindanamines and Spiroindanimides
DE60014603T2 (de) * 1999-03-12 2006-02-16 Boehringer Ingelheim Pharmaceuticals, Inc., Ridgefield Heterocyklischer harnstoff und verwandte verbindungen als entzündungshemmende mittel
SE0200356D0 (sv) * 2002-02-05 2002-02-05 Astrazeneca Ab Novel use
SE0200411D0 (sv) * 2002-02-05 2002-02-05 Astrazeneca Ab Novel use
GB2388540A (en) 2002-05-17 2003-11-19 Bayer Ag New use of Ramatroban
PL376156A1 (en) 2002-10-04 2005-12-27 Millennium Pharmaceuticals, Inc. Pgd2 receptor antagonists for the treatment of inflammatory diseases
ES2263015T3 (es) 2002-10-21 2006-12-01 Warner-Lambert Company Llc Derivados de tetrahidroquinolina como antagonistas de crth2.
DK1471057T3 (da) 2003-04-25 2006-05-15 Actimis Pharmaceuticals Inc Pyrimidinyleddikesyrederivater, der er egnede til behandlingen af sygdomme medieret af CRTH2
SE0301569D0 (sv) 2003-05-27 2003-05-27 Astrazeneca Ab Novel compounds
SE0301650D0 (sv) 2003-06-04 2003-06-04 Astrazeneca Ab Novel compounds
SE0301653D0 (sv) 2003-06-05 2003-06-05 Astrazeneca Ab Novel compounds
US20050038070A1 (en) 2003-07-09 2005-02-17 Amgen Inc. Asthma and allergic inflammation modulators
CA2563707A1 (en) 2004-04-20 2005-11-03 Pfizer Inc. Method of treating neuropathic pain using a crth2 receptor antagonsit

Also Published As

Publication number Publication date
NZ562772A (en) 2010-01-29
CA2602965A1 (en) 2006-11-30
AU2006251138A1 (en) 2006-11-30
DK1891075T3 (da) 2011-12-19
CA2602965C (en) 2013-12-31
PT1891075E (pt) 2011-11-10
US8236963B2 (en) 2012-08-07
JP2008542238A (ja) 2008-11-27
MX2007014256A (es) 2008-03-26
CN101300259A (zh) 2008-11-05
EP1891075A1 (en) 2008-02-27
PL1891075T3 (pl) 2011-12-30
ES2375614T3 (es) 2012-03-02
UA90145C2 (ru) 2010-04-12
RU2478639C2 (ru) 2013-04-10
BRPI0610209A2 (pt) 2010-06-01
CN101300259B (zh) 2013-08-28
KR101333861B1 (ko) 2013-11-28
ZA200709819B (en) 2009-09-30
KR20080031191A (ko) 2008-04-08
JP5567268B2 (ja) 2014-08-06
EP1891075B1 (en) 2011-10-19
ATE529429T1 (de) 2011-11-15
AU2006251138C1 (en) 2013-08-29
AU2006251138B2 (en) 2012-08-09
US20090318486A1 (en) 2009-12-24
WO2006125784A1 (en) 2006-11-30
RU2007147430A (ru) 2009-06-27

Similar Documents

Publication Publication Date Title
AR055959A1 (es) Derivados espiro para la modulacion de actividad de crth2
AR044078A1 (es) Dihidroquinazolinas sustituidas
NO20075623L (no) Benzodioksan- og benzodioksolanderivater og deres anvendelse
PE20080671A1 (es) DERIVADOS DE 2-ARIL-6-FENIL-IMIDAZO[1,2-a]PIRIDINAS, SU PREPARACION Y SU APLICACION EN TERAPEUTICA
AR049646A1 (es) Derivados de sulfamato y sulfamida utiles para el tratamiento de la epilepsia y trastornos relacionados
AR050644A1 (es) Derivados de anilina sustituidos
DK1313695T3 (da) Estere af 5-aminolevulinsyre som fotosensibiliserende midler i fotokemoterapi
CO5721002A2 (es) Derivados de acido 3-(4-benciloxifenil) propanoico
AR063311A1 (es) Compuestos organicos
ES2530943T3 (es) Derivados de la cromenona con actividad antitumoral
DK1981874T3 (da) Aminophenylderivater som nye inhibitorer af histondeacetylase
CO5611110A2 (es) Mimeticos de glucocorticoides, procedimientos para su preparacion, composiciones farmaceuticas y usos de los mismos
CO6190609A2 (es) Compuestos de urea policiclicos antibacterianos
AR031627A1 (es) Activadores heteroaromaticos fusionados de la glucoquinasa
AR057906A1 (es) Derivados de pirimidona biciclicos sustituidos y su uso en la preparacion de medicamentos para el tratamiento de enfermedades mediadas por la actividad anormal de gsk3beta.
AR051392A1 (es) Antagonistas no peptidicos de bradiquinina y composiciones farmaceuticas de los mismos
AR063128A1 (es) Compuestos de aril - indol sustituido y sus usos metabolitosde tipo quinurenina / quinurenina como agentes terapeuticos
AR059032A1 (es) Combinacion de derivados de triazina y sensibilizadores de insulina
AR064521A1 (es) Activador de glucoquinasa
DK1412354T3 (da) Derivater af triazolylimidazopyridin og af triazolylpurinerne, der er egnede som ligander for adenosin A2a?-receptoren og deres anvendelse som medikamenter
AR076008A1 (es) Derivados de hidroximetil-isoxazol moduladores de receptores gaba a, composiciones farmaceuticas que los contienen, metodo para prepararlos y uso de los mismos para el tratamiento del alzheimer y otros trastornos cognitivos.
AR054102A1 (es) Derivados de fenil-piperazina-metanona. procesos de obtencion y composiciones farmaceuticas
AR066604A1 (es) Derivados de arilamida pirimidona, medicamentos que los contienen y usos terapeuticos para prevenir y/o tratar enfermedades neurodegenerativas fundamentalmente.
AR072793A1 (es) Compuestos de aril isoxazol con actividades antitumorales
AR059030A1 (es) Combinacion de derivados de triazina y estimuladores de la secrecion de insulina

Legal Events

Date Code Title Description
FB Suspension of granting procedure